NY-UNIFRAX/CLEARLAKE
11.11.2021 13:02:09 CET | Business Wire | Press release
Unifrax , a leading manufacturer of high-performance specialty materials, today introduced its Battery Advisory Board, which will meet regularly to provide strategic guidance as Unifrax grows its battery portfolio and enters the silicon anode market with its new SiFAB™ Silicon Fiber Anode Battery Technology .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005282/en/
SiFAB, a scalable proprietary silicon anode battery technology demonstrated in wide-reaching applications, including electric vehicles, power tools, smartphones, personal computers, medical devices and aviation, can deliver up to 20% increase in gravimetric energy density in lithium-ion batteries. It has proven through advanced testing high reversible capacity of greater than 1,000 mAh/g. Unifrax recently broke ground on its first production line located in New Carlisle, IN, which is expected to come online in early 2022.
This transformational technology becomes part of a robust battery portfolio that also consists of world class thermal management products and separator media.
The advisory board will bring together four highly experienced professionals and visionaries in the battery technology, engineering and operations space, with experts from the nation’s top universities and esteemed technology companies.
Unifrax’s Battery Advisory Board will include:
- Dr. Prabhakar Patil, former CEO, LG Chem Power, and Chief Engineer of Hybrid Technologies, Ford Motor Company. Dr. Patil previously served as CEO of LG Chem Power (LGCPI) for 10 years. Prior to joining LGCPI in 2005, Dr. Patil spent 27 years of his professional career at Ford Motor Company in various engineering and management positions. He served as Chief Engineer for Ford’s hybrid technologies during 2003 and was also Chief Engineer for the Ford Escape Hybrid from 1998 to 2003.
- Rita Lane, former Vice President of Operations, Apple Inc., and Senior Vice President of Integrated Supply Chain, Motorola. Ms. Lane has more than 30 years of experience building and leading global hardware operations and supply chain teams for Fortune 100 companies. From 2008 until her retirement in 2014, she served as Vice President of Operations at Apple, where she oversaw the launch of the iPad and manufacturing of the Mac desktop and accessories product lines. From 2006 to 2008, Lane was Chief Procurement Officer and SVP, Supply Chain, at Motorola. Prior to working at Motorola, Lane held various senior-level operations roles at IBM for more than 10 years.
- Dr. Arumugam “Ram” Manthiram, Professor, University of Texas at Austin. Dr. Manthiram is Director of the Texas Materials Institute and the Materials Science and Engineering Graduate Program. With more than 35 years of experience, Dr. Manthiram’s research is focused on the development of low-cost, high-performance materials for batteries. He is a globally recognized leader in cathode materials for lithium-ion batteries. He has authored more than 850 journal articles. Dr. Manthiram holds the Cockrell Family Regents Chair in Engineering #5. He delivered the lecture on behalf of Nobel Prize recipient John B. Goodenough in 2019 in Stockholm for his work on lithium-ion batteries.
- Dr. Jennifer Rupp, Professor of Electrochemical Materials, Massachusetts Institute of Technology (MIT) and TU Munich (TUM). Dr. Rupp is Associate Professor of Electrochemical Materials in the Departments of Materials Science and Engineering at MIT and in the Department of Chemistry at TUM, and technical director of TUM Int. Energy. Dr. Rupp gave keynote lectures at Nature Energy and Sustainability conferences, Gordon Research keynote lectures in ceramics and electrochemistry and at the Royal Chemical Society, and presented on battery, information and energy technology at the World Economic Forum. Dr. Rupp’s team's current research focuses are on solid-state material design and tuning of structure-property relations for novel energy and information devices and operation schemes. In 2021, Rupp was invited to become a Fellow of the Royal Society of Chemistry (FRSC).
“We’re thrilled to have put together such a talented and influential advisory board,” said John Dandolph, CEO, Unifrax. “Their depth of experience and perspective in lithium-ion battery technology and novel chemistries spans multiple industries, including portable electronics, consumer devices and EVs, which will help us navigate the complex supply chains as we bring hundreds of metric tons of capacity to the market in the near future. I look forward to partnering with this group of industry icons as we transform battery safety, capacity, power, and charge times.”
To learn more about SiFAB or to follow the latest updates on the technology, visit www.sifab.com .
About Unifrax
Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has over 60 global manufacturing facilities and employs 5,600+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn and Facebook .
About Clearlake
Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit, and other related strategies. With a sector-focused approach, the firm seeks to partner with world-class management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are technology, industrials, and consumer. Clearlake currently has approximately $50 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005282/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom